Context:
The Indian Council of Medical Research (ICMR) has launched “Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect”, described as India’s largest biomedical innovation and technology transfer platform, at an event in New Delhi. The platform is built to close the long-standing gap between scientific research in laboratories and actual products in the market, by helping ICMR institutes, universities, and startups transfer their healthcare technologies to industry partners for large-scale manufacturing and public use.
Key Highlights
- Initiative: Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect.
- Launched by: Indian Council of Medical Research (ICMR).
- Venue of launch: New Delhi.
- Stated scale: India’s largest biomedical innovation and technology transfer platform.
Main objectives:
Free live session
NABARD Sprint 60: the 2025 cut-offs and your 60-day Phase I plan
8 of the top 10 in NABARD Grade A 2025, Rank 1 included, and Rank 1 back to back before that in 2021 and 2022: all prepared with C4S. The 2025 cycle was the toughest on record at every stage. This session reads those numbers properly and turns them into a 60-day, week-by-week plan for Phase I.
In 5 days · Sun, 18 Oct at 7:30 PM IST · 75 minutes · free
| Objective | What it means |
|---|---|
| Bridge research and industry | Move technologies from ICMR institutes and labs into commercial production |
| Affordable healthcare | Bring down costs by enabling indigenous manufacturing |
| Strengthen the IP ecosystem | Support patent filing, protection, and licensing |
| Public-private partnerships | Bring researchers, startups, and industry on one platform |
| Support Viksit Bharat 2047 | Build an innovation-led, self-reliant health economy |
A clean PDF of this page with the C4S header — it opens right away, and the link comes to your WhatsApp too.
Five core features:
| Feature | Detail |
|---|---|
| Technology Transfer Platform | Direct transfer of biomedical technologies from research institutions to industry for large-scale production |
| Indigenous Healthcare Innovation | More than 100 Indian technologies showcased across diagnostics, therapeutics, vaccines, and medical devices |
| Public Health Focus | Technologies cover diseases like typhoid, paratyphoid, tuberculosis, Japanese Encephalitis, Mpox, KFD, and Chandipura virus |
| IP Ecosystem | Release of the Indian Biomedical Patent Landscape Report and the Technology Compendium |
| Public-Private Partnership | Brings together researchers, startups, and healthcare companies to expand India’s biomedical manufacturing base |
Diseases covered by the showcased technologies:
- Typhoid and Paratyphoid (waterborne bacterial infections).
- Tuberculosis (TB), a long-standing public health priority.
- Japanese Encephalitis (JE), a mosquito-borne viral disease.
- Mpox (formerly Monkeypox), a global concern.
- Kyasanur Forest Disease (KFD), a tick-borne viral haemorrhagic fever endemic to parts of Karnataka and the Western Ghats.
- Chandipura virus, a vector-borne virus that has caused outbreaks in Gujarat and other states.
Background Concepts (Q&A)
What is the Indian Council of Medical Research (ICMR)?
The Indian Council of Medical Research (ICMR) is India’s apex body for the formulation, coordination, and promotion of biomedical research. It functions under the Department of Health Research, Ministry of Health and Family Welfare. Headquartered in New Delhi, ICMR was originally established in 1911 as the Indian Research Fund Association (IRFA), and renamed ICMR in 1949. It runs a network of about 27 national institutes focused on specific diseases (such as tuberculosis, virology, vector-borne diseases, cholera, leprosy, cancer, food and drug toxicology, occupational health, and statistics) and six Regional Medical Research Centres. ICMR played a key role in India’s COVID-19 response, clinical-trial guidelines, National Ethical Guidelines for Biomedical Research, and disease surveillance.
Practice MCQs
Q1. With reference to the recently launched “Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect”, consider the following statements:
- It has been launched by the Indian Council of Medical Research (ICMR).
- It is described as India’s largest biomedical innovation and technology transfer platform.
- It aims to bridge the gap between scientific research and industrial commercialisation in healthcare.
- The platform showcased over 100 Indian biomedical technologies across diagnostics, therapeutics, vaccines, and medical devices.
How many of the above statements are correct? (a) Only one (b) Only two (c) Only three (d) All four (e) None
Q2. Consider the following statements about the Indian Council of Medical Research (ICMR):
- ICMR is India’s apex body for the formulation, coordination, and promotion of biomedical research.
- It functions under the Department of Health Research, Ministry of Health and Family Welfare.
- It was originally established in 1911 as the Indian Research Fund Association (IRFA).
- ICMR is responsible for the regulation of mutual funds and securities markets in India.
Which of the above are correct? (a) 1, 2 and 3 only (b) 1, 3 and 4 only (c) 2 and 4 only (d) 1 and 4 only (e) All four
Q3. Consider the following diseases for which Indian biomedical technologies were showcased under the I2I Connect platform:
- Kyasanur Forest Disease (KFD)
- Chandipura virus
- Japanese Encephalitis (JE)
- Mpox
Which of the above were covered by the showcased technologies? (a) 1, 2 and 3 only (b) 1, 3 and 4 only (c) 2 and 4 only (d) 1 and 4 only (e) All four
Q4. With reference to technology transfer in biomedical research, consider the following statements:
- Technology transfer involves moving a scientific invention from a research lab to industry for production and distribution.
- The process typically includes disclosure, patent filing, licensing, and scale-up.
- Patent licensing usually involves upfront fees, milestone payments, and royalties for the inventor or institution.
- Patent Mitra (I2I Connect) is designed to facilitate the technology transfer process for biomedical innovations in India.
Which of the above are correct? (a) 1, 2 and 3 only (b) 1, 3 and 4 only (c) 2 and 4 only (d) 1 and 4 only (e) All four
Answer Key
- (d), All four statements are correct.
- (a), Statements 1, 2, 3 are correct. Statement 4 is wrong; the regulation of mutual funds and securities markets is the role of SEBI, NOT ICMR. ICMR’s role is in biomedical research, public health, and disease control.
- (e), All four statements are correct.
- (e), All four statements are correct.
